Harmony Biosciences Holdings (HRMY)vsRegeneron Pharmaceuticals Inc (REGN)
HRMY
Harmony Biosciences Holdings
$27.59
+1.81%
HEALTHCARE · Cap: $1.60B
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 1552% more annual revenue ($14.34B vs $868.45M). REGN leads profitability with a 31.4% profit margin vs 18.3%. HRMY trades at a lower P/E of 10.2x. HRMY earns a higher WallStSmart Score of 62/100 (C+).
HRMY
Buy62
out of 100
Grade: C+
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-98.5%
Fair Value
$18.43
Current Price
$27.59
$9.16 premium
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Safe zone — low bankruptcy risk
Every $100 of equity generates 21 in profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 21.1% year-over-year
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
Smaller company, higher risk/reward
Earnings declined 55.0%
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : HRMY
The strongest argument for HRMY centers on P/E Ratio, Altman Z-Score, Return on Equity. Profitability is solid with margins at 18.3% and operating margin at 15.8%. Revenue growth of 21.1% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : HRMY
The primary concerns for HRMY are Market Cap, EPS Growth.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
HRMY profiles as a growth stock while REGN is a value play — different risk/reward profiles.
HRMY carries more volatility with a beta of 0.91 — expect wider price swings.
HRMY is growing revenue faster at 21.1% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
HRMY scores higher overall (62/100 vs 58/100), backed by strong 18.3% margins and 21.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harmony Biosciences Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?